{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"60.0","value":"22.2"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"45.9","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"33.6","value":"0.0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"33.6","value":"0.0"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"33.6","value":"0.0"},{"groupId":"OG006","lowerLimit":"2.5","upperLimit":"17.0","value":"7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"65"}],"units":"Participants"}],"description":"BOR is defined as the participant's best confirmed response (CR or PR) over the treatment period as assessed by the investigator per RECIST 1.1 or RANO. As per RECIST 1.1, CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Ewing sarcoma received lenvatinib 14 mg/m\\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.","id":"OG000","title":"Ewing Sarcoma"},{"description":"Participants with rhabdomyosarcoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG001","title":"Rhabdomyosarcoma"},{"description":"Participants with high grade glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG002","title":"High Grade Glioma"},{"description":"Participants with diffuse midline glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG003","title":"Diffuse Midline Glioma"},{"description":"Participants with medulloblastoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG004","title":"Medulloblastoma"},{"description":"Participants with ependymoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG005","title":"Ependymoma"},{"description":"Participants with other solid tumors received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG006","title":"Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma"}],"paramType":"NUMBER","populationDescription":"All participants who had measurable disease present at baseline and at least one efficacy assessment, unless they discontinued prior to the first efficacy assessment due to progressive disease.","reportingStatus":"POSTED","timeFrame":"Up to approximately 21 months","title":"Best Overall Response (BOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}